Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2015 (2015), Article ID 834124, 7 pages
http://dx.doi.org/10.1155/2015/834124
Research Article

Effect of Luteolin on 11Beta-Hydroxysteroid Dehydrogenase in Rat Liver and Kidney

1Department of Pharmacy, The First Affiliated Hospital, Sun Yat-Sen University, 58 Zhongshan No. 2 Road, Guangzhou, Guangdong 510080, China
2The Fourth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 511447, China
3Department of Pharmacy, Guangzhou Xinhai Hospital, Guangzhou, Guangdong 510300, China

Received 1 April 2015; Revised 3 June 2015; Accepted 11 June 2015

Academic Editor: Yoshiyuki Kimura

Copyright © 2015 Lei Tang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. W. Hunter and M. A. Bailey, “Glucocorticoids and 11β-hydroxysteroid dehydrogenases: mechanisms for hypertension,” Current Opinion in Pharmacology, vol. 21, pp. 105–114, 2015. View at Publisher · View at Google Scholar
  2. J. Q. Rose, A. M. Yurchak, and W. J. Jusko, “Dose dependent pharmacokinetics of prednisone and prednisolone in man,” Journal of Pharmacokinetics and Biopharmaceutics, vol. 9, no. 4, pp. 389–417, 1981. View at Google Scholar · View at Scopus
  3. M. Conti, F. J. Frey, G. Escher, C. Marone, and B. M. Frey, “Renal handling of prednisolone/prednisone: effect of steroid dose and 11β-hydroxysteroid dehydrogenase,” Nephrology Dialysis Transplantation, vol. 9, no. 11, pp. 1622–1628, 1994. View at Google Scholar · View at Scopus
  4. M. E. Pickup, “Clinical pharmacokinetics of prednisone and prednisolone,” Clinical Pharmacokinetics, vol. 4, no. 2, pp. 111–128, 1979. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Ferrari, “The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1802, no. 12, pp. 1178–1187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. P. M. Stewart and Z. S. Krozowski, “11β-hydroxysteroid dehydrogenase,” Vitamins and Hormones, vol. 57, pp. 249–324, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Quinkler, W. Oelkers, and S. Diederich, “Clinical implications of glucocorticoid metabolism by 11β-hydroxysteroid dehydrogenases in target tissues,” European Journal of Endocrinology, vol. 144, no. 2, pp. 87–97, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. Z. Krozowski, K. X. Z. Li, K. Koyama et al., “The type I and type II 11β-hydroxysteroid dehydrogenase enzymes,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 69, no. 1–6, pp. 391–401, 1999. View at Publisher · View at Google Scholar · View at Scopus
  9. A. N. Amweg, N. R. Salvetti, M. L. Stangaferro et al., “Ovarian localization of 11β-hydroxysteroid dehydrogenase (11βHSD): effects of ACTH stimulation and its relationship with bovine cystic ovarian disease,” Domestic Animal Endocrinology, vol. 45, no. 3, pp. 126–140, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. A. Staab and E. Maser, “11β-Hydroxysteroid dehydrogenase type 1 is an important regulator at the interface of obesity and inflammation,” Journal of Steroid Biochemistry and Molecular Biology, vol. 119, no. 1-2, pp. 56–72, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Odermatt and L. G. Nashev, “The glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: physiological and toxicological considerations,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 119, no. 1-2, pp. 1–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. V. Sharp, L. M. Thurston, R. C. Fowkes, and A. E. Michael, “Expression and activities of 11βHSD enzymes in the testes and reproductive tracts of sexually immature male pigs,” Journal of Steroid Biochemistry and Molecular Biology, vol. 115, no. 3–5, pp. 98–106, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. R.-S. Ge, Q. Dong, E.-M. Niu et al., “11β-hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid action at physiological levels of substrate,” Endocrinology, vol. 146, no. 6, pp. 2657–2664, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Odermatt and D. V. Kratschmar, “Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: an overview,” Molecular and Cellular Endocrinology, vol. 350, no. 2, pp. 168–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. J. W. Tomlinson, M. Sherlock, B. Hughes et al., “Inhibition of 11β-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis,” Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 3, pp. 857–864, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Ferrari, “The role of 11β-hydroxysteroid dehydrogenase type 2 in human hypertension,” Biochimica et Biophysica Acta, vol. 1802, no. 12, pp. 1178–1187, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Lacey, J. Bohday, S. M. R. Fonseka, A. I. Ullah, and S. A. Whitehead, “Dose-response effects of phytoestrogens on the activity and expression of 3β-hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 96, no. 3-4, pp. 279–286, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Xu, B. Wei, X. Fu et al., “Effect of Eclipta prostrata on 11beta-hydroxysteroid dehydrogenase in rat liver and kidney,” Evidence-Based Complementary and Alternative Medicine, vol. 2014, Article ID 651053, 9 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Ugocsai, A. Varga, P. Molnár, S. Antus, and J. Molnár, “Effects of selected flavonoids and carotenoids on drug accumulation and apoptosis induction in multidrug-resistant colon cancer cells expressing MDR1/LRP,” In Vivo, vol. 19, no. 2, pp. 433–438, 2005. View at Google Scholar · View at Scopus
  20. J. Chen, H. Lin, and M. Hu, “Metabolism of flavonoids via enteric recycling: role of intestinal disposition,” Journal of Pharmacology and Experimental Therapeutics, vol. 304, no. 3, pp. 1228–1235, 2003. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Shimada, K. Miura, and Y. Imamura, “Characteristics and inhibition by flavonoids of 20α-hydroxysteroid dehydrogenase activity in mouse tissues,” Life Sciences, vol. 78, no. 25, pp. 2931–2936, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Courtney, P. M. Stewart, M. Toh, M.-N. Ndongo, R. A. Calle, and B. Hirshberg, “Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor,” Journal of Clinical Endocrinology and Metabolism, vol. 93, no. 2, pp. 550–556, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Vogt, B. Dick, H.-P. Marti, F. J. Frey, and B. M. Frey, “Reduced 11β-hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome,” Nephrology Dialysis Transplantation, vol. 17, no. 5, pp. 753–758, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Homma, A. Tanaka, K. Hino et al., “Assessing systemic 11β-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure,” Metabolism: Clinical and Experimental, vol. 50, no. 7, pp. 801–804, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Quinkler, D. Zehnder, J. Lepenies et al., “Expression of renal 11β-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function,” European Journal of Endocrinology, vol. 153, no. 2, pp. 291–299, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. M. N. Kerstens, H. Buter, G. J. Navis, and R. P. F. Dullaart, “11β-hydroxysteroid dehydrogenase activity in proteinuric patients and the effect of angiotensin-II receptor blockade,” European Journal of Clinical Investigation, vol. 32, no. 7, pp. 513–518, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. B. Vogt, B. Dick, V. N'Gankam, F. J. Frey, and B. M. Frey, “Reduced 11β-hydroxysteroid dehydrogenase activity in patients with the nephrotic syndrome,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 2, pp. 811–814, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. N. L. Yeyati, M. E. Altuna, M. C. Damasco, and M. A. M. Laughlin, “Role of 11β-hydroxysteroid dehydrogenase 2 renal activity in potassium homeostasis in rats with chronic renal failure,” Brazilian Journal of Medical and Biological Research, vol. 43, no. 1, pp. 52–56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Ergang, P. Leden, K. Vagnerová et al., “Local metabolism of glucocorticoids and its role in rat adjuvant arthritis,” Molecular and Cellular Endocrinology, vol. 323, no. 2, pp. 155–160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. W. J. Inder, V. R. Obeyesekere, F. P. Alford, and C. Jang, “Skeletal muscle 11βHSD1 activity of nondiabetic subjects is unaltered in central obesity-associated insulin resistance,” Hormone and Metabolic Research, vol. 43, no. 4, pp. 257–260, 2011. View at Publisher · View at Google Scholar · View at Scopus